Abstract
Background: Regular outpatient visits to healthcare facilities for benzathine penicillin injections are the primary means of secondary prevention for patients with Rheumatic Heart Disease (RHD). It has been widely demonstrated that individual access to healthcare has been disrupted by the COVID-19 outbreak, but its impact on RHD patients has not been studied. Methods: Using a stratified random sampling strategy, we conducted a baseline and follow-up survey of RHD patients in Western Uganda between November 2019 and February 2020, and November 2020 and February 2021, and obtained 486 month-patient outpatient records. A fixed effect model and event-study analysis method were employed to investigate the impact of the COVID-19 pandemic on RHD patients' secondary prevention. Results: Prior to the outbreak of COVID-19, the average number of secondary prevention visits for RHD patients in Uganda were 9.48 per patient per year, which was far below the criteria of clinical guidelines. The secondary prevention visits decreased by an average of 0.12 visits per month in the COVID-19 pandemic, but the decrease was not statistically significant (P>0.05). The number of monthly secondary prevention visits among patients with RHD exhibited a gradual upward trend over time. The number of secondary prevention visits increased significantly (P<0.05) in the eight months following the COVID-19 outbreak in western Uganda. Conclusions: RHD patients in Western Uganda failed to adhere to the recommended frequency of secondary antibiotic prophylaxis prior to the outbreak of the COVID-19 pandemic, which decreased further during the pandemic. Improving the accessibility and convenience of treatment for RHD patients is a crucial step in enhancing the frequency of secondary prevention. Future pandemic preparations should consider the demands of secondary prevention among RHD patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the American Heart Association (17SFRN33670611, 17SFRN33630027).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Makerere University School of Medicine Research and Ethics Committee (REC RF 2018-082) and by the Uganda National Council for Science and Technology (SS 5081). Written informed consent to participate in this study was provided by the participants or, in the case of minors, their legal guardian or next of kin. In addition, the University of Washington Human Subjects Division approved an earlier version of this study (STUDY00002855) that did not include subjects under the age of ten.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos